1120 related articles for article (PubMed ID: 19034014)
1. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
[TBL] [Abstract][Full Text] [Related]
2. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.
Hartwig UF; Nonn M; Khan S; Link I; Huber C; Herr W
Biol Blood Marrow Transplant; 2008 Jan; 14(1):99-109. PubMed ID: 18158966
[TBL] [Abstract][Full Text] [Related]
3. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings.
Davies JK; Koh MB; Lowdell MW
Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224
[TBL] [Abstract][Full Text] [Related]
4. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
[TBL] [Abstract][Full Text] [Related]
5. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes.
Hartwig UF; Nonn M; Khan S; Meyer RG; Huber C; Herr W
Bone Marrow Transplant; 2006 Feb; 37(3):297-305. PubMed ID: 16327814
[TBL] [Abstract][Full Text] [Related]
6. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
7. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
8. Antigen presentation by interferon-gamma-treated endothelial cells and fibroblasts: differential ability to function as antigen-presenting cells despite comparable Ia expression.
Geppert TD; Lipsky PE
J Immunol; 1985 Dec; 135(6):3750-62. PubMed ID: 3934267
[TBL] [Abstract][Full Text] [Related]
9. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis.
Koh MB; Prentice HG; Lowdell MW
Bone Marrow Transplant; 1999 May; 23(10):1071-9. PubMed ID: 10373075
[TBL] [Abstract][Full Text] [Related]
10. Mismatched human leukocyte antigen class II-restricted CD8⁺ cytotoxic T cells may mediate selective graft-versus-leukemia effects following allogeneic hematopoietic cell transplantation.
Hirosawa T; Torikai H; Yanagisawa M; Kamei M; Imahashi N; Demachi-Okamura A; Tanimoto M; Shiraishi K; Ito M; Miyamura K; Shibata K; Kikkawa F; Morishima Y; Takahashi T; Emi N; Kuzushima K; Akatsuka Y
Cancer Sci; 2011 Jul; 102(7):1281-6. PubMed ID: 21466613
[TBL] [Abstract][Full Text] [Related]
11. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
[TBL] [Abstract][Full Text] [Related]
12. Primary human keratinocytes as targets in predicting acute graft-versus-host disease following HLA-identical bone marrow transplantation.
van Dijk AM; Kessler FL; Verdonck LF; Stadhouders-Keet SA; van Lier RA; de Gast GC; Otten HG
Br J Haematol; 2000 Dec; 111(3):791-6. PubMed ID: 11122139
[TBL] [Abstract][Full Text] [Related]
13. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
[TBL] [Abstract][Full Text] [Related]
14. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
15. Minor histocompatibility antigens, defined by graft-vs.-host disease-derived cytotoxic T lymphocytes, show variable expression on human skin cells.
De Bueger M; Bakker A; Van Rood JJ; Goulmy E
Eur J Immunol; 1991 Nov; 21(11):2839-44. PubMed ID: 1682155
[TBL] [Abstract][Full Text] [Related]
16. In vitro methotrexate as a practical approach to selective allodepletion.
Sathe A; Ortega SB; Mundy DI; Collins RH; Karandikar NJ
Biol Blood Marrow Transplant; 2007 Jun; 13(6):644-54. PubMed ID: 17531774
[TBL] [Abstract][Full Text] [Related]
17. Specificity of T cells invading the skin during acute graft-vs.-host disease after semiallogeneic bone marrow transplantation.
Gaschet J; Mahé B; Milpied N; Devilder MC; Dréno B; Bignon JD; Davodeau F; Hallet MM; Bonneville M; Vié H
J Clin Invest; 1993 Jan; 91(1):12-20. PubMed ID: 8423212
[TBL] [Abstract][Full Text] [Related]
18. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.
Wehler TC; Nonn M; Brandt B; Britten CM; Gröne M; Todorova M; Link I; Khan SA; Meyer RG; Huber C; Hartwig UF; Herr W
Blood; 2007 Jan; 109(1):365-73. PubMed ID: 16931626
[TBL] [Abstract][Full Text] [Related]
19. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction.
Montagna D; Daudt L; Locatelli F; Montini E; Turin I; Lisini D; Giorgiani G; Bernardo ME; Maccario R
Cancer Res; 2006 Jul; 66(14):7310-6. PubMed ID: 16849581
[TBL] [Abstract][Full Text] [Related]
20. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
